Published 14:00 IST, September 20th 2023
Aurobindo Pharma's facility receives US FDA Form 483 with procedural observation
Aurobindo Pharma, the parent company of APL Healthcare Limited, in the filing, has affirmed that it will promptly address the observation raised by the US FDA.
![Aurobindo Pharma](https://img.republicworld.com/tr:w-800,h-450,q-75,f-auto/rimages/3cnzhkkmjufbvlwe_1695198589_16_9.jpeg)
Image credit: Republic | Image:
self
- Listen to this article
- 2 min read
Advertisement
14:00 IST, September 20th 2023